Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Improving Pipeline of New Pharmaceutical Products – Main Priority of Manufacturers

Various recombinant vaccines manufacturers have allotted a new capital framework to help shape their strategic priorities. Improving pipelines for new pharmaceutical products is the main priority for recombinant vaccines manufacturers and has the potential for a marked improvement in their performance. Manufacturers are investing behind their key recombinant vaccines, which is expected to drive growth the growth of the market in the coming years.

Increasing government initiatives for using recombinant vaccines in North, Europe, Latin America, and Asia pacific region is fueling the growth of the Recombinant Vaccines market. The growing demand for sustainable & optimized healthcare has increased the demand for Recombinant Vaccines. Moreover, ease of application of Recombinant Vaccines and the availability of Recombinant Vaccines through traditional supply chains are leading to increasing adoption rates of Recombinant Vaccines among distribution channel.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Lucrative Absolute Dollar Opportunities for Key Players in the Recombinant Vaccines Market

Recombinant vaccines haven’t infiltrated healthcare settings, especially in Middle East, Africa, and APEJ. Large number of patients are not aware about recombinant vaccines in not only the developing economies, but also a considerable portion of developed economies. Market players are yet to market recombinant vaccines efficiently in order to exploit their full market potential.

Awareness, advertisement, and proper marketing and are expected to help grab lucrative revenue opportunities over the forecast period. Although the adoption rate of recombinant vaccines is moderate in hospital settings globally, it poses a great market potential for manufacturers.

Recombinant Vaccines to Gain Popularity over the Forecast Period

Recombinant vaccines are projected to gain popularity as they provide great benefits for the patient, reduced side effect profiles, and reduced costs associated with therapeutic intervention as the hospital expenditure is reduced using recombinant vaccines.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

80% Revenue Contribution by Leading Manufacturers in the Recombinant Vaccines Market

The recombinant vaccines market is mainly dominated by global manufactures. These manufacturers of recombinant vaccines are competing based on adoption of their respective recombinant vaccines. The increasing awareness about recombinant vaccines and a growing demand for optimized & sustainable healthcare has increased the revenue opportunity for the global manufacturers.

Companies like GlaxoSmithKline plc, and Merck & Co Inc, hold more than 80% revenue share in the global recombinant vaccines market. Launching novel products is one of the main focus of key market players. Also, companies operating in the recombinant vaccines market are collaborating with retailers and local distributors in order to increase the penetration of their respective recombinant vaccines.

Recombinant Vaccines Market Witnessing Considerable Growth in Asia Pacific

According to the discussions held with key opinion leaders in the recombinant vaccines market, a substantial growth has been witnessed in Asia Pacific market for recombinant vaccines market. Manufacturers in China & APEC are estimated to grow significantly in the recombinant vaccines market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Existing Alternate Product Categories Pose Challenges to the Growth of the Recombinant Vaccines Market

Recombinant vaccines face stiff competition from parallel product categories such as live attenuated vaccines. These vaccines offer broad spectrum immunity, and also reduce the number of dosages required. Attenuated vaccines are also known to be effective in stimulating both humoral as well as cellular immune responses. However, live attenuated vaccines in recombinant form could lead to disease transmission in immune-compromised hosts, which at times deter usage.

Recombinant Vaccines Market

Competitive Landscape

The company’s report titled “Recombinant Vaccines Market” provides detailed information about the growth parameters of the companies operating in the recombinant vaccines market. It includes detailed assessment of the competitive environment in the recombinant vaccines market.

The market study provides comprehensive data on each stakeholder in the recombinant vaccines market, including GlaxoSmithKline Biologicals, MERCK & CO., INC, Dynavax Technologies Corporation, Sanofi Pasteur, Bharat Biotech, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., LG Chem, Sinovac Biotech Ltd, Pfizer, C.H. Boehringer Sohn AG & Co.KG. The report provides readers with all-encompassing data on each recombinant vaccine manufacturer’s revenue shares, winning strategies, and latest information on key strategies in the recombinant vaccines market.

Definition

Subunit recombinant vaccines are derived from killed vaccines. Their synthesis is non-toxic in nature. They contain highly immunogenic microbial antigens and are made with the help of recombinant DNA technology. Worth noting that the antigen component of subunit vaccines is covalently linked to a carrier, mostly a protein.

Attenuated recombinant vaccines are designed to specifically attenuate the microbe. Advantage of this type is mutant lesion in the microbe is specific, rather than randomly placed. These vaccines can be produced rapidly to meet sudden demands. Also it is easy to track the surveillance of these vaccines to revert back to virulence.

About the Report

The study on the recombinant vaccines market was recently published by the company, which provides comprehensive information about the most important market dynamics that prove instrumental in the growth of the recombinant vaccines market during 2018-2026. Companies in the recombinant vaccines market can find the most accurate quantitative and qualitative information about the growth parameters of the other recombinant vaccine manufacturers, which can help them develop data-driven business strategies in the coming future.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors affecting the recombinant vaccines market during the forecast period. Additionally, the report also contains valuable information that can provide recombinant vaccines manufacturers with answers to critical questions, such as

  • Which types of products account for the maximum demand for recombinant vaccines market? Why is it so?
  • Why are the sales of recombinant vaccines services and products highest in North America? What are the factors customers seek in Recombinant Vaccines?
  • Which factors are influencing the strategies of players in the recombinant vaccines market?
  • What are the current trends adopted by various companies?
  • What are the strategies being applied by the manufacturers in order to sustain themselves in the competitive market?

Research Methodology

The process of market research followed by the company commences with extensive secondary research of the recombinant vaccines market. We have obtained industry-validated, historic, and current data about the demand for recombinant vaccines across the globe. Comprehensive secondary research was followed by extensive and in-depth primary research, where detailed information about the recombinant vaccines market was obtained in terms of value (US$ Million).

Based on thorough secondary and primary research of the growth parameters of the recombinant vaccines market, we have come up with the most precise forecast on how the recombinant vaccines market will grow during the forecast period.

Segmentation

The report on the recombinant vaccines market provides salient information on market players. The recombinant vaccines market is segmented by region, product type, application, and distribution channel, to analyze segment-wise growth of the recombinant vaccines market. Based on regions, the recombinant vaccines market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East & Africa (MEA).

The recombinant vaccines market by product type is segmented intosubunit recombinant vaccines, attenuated recombinant vaccines, vector recombinant vaccines. By application, the recombinant vaccines market is segregated into human, and veterinary recombinant vaccines. By distribution channel, the recombinant vaccines market is segregated into hospitals, private clinics & dispensaries, retail pharmacies & others.

Frequently Asked Questions

What is the Nature of Competition in the Recombinant Vaccines Market?

The recombinant vaccines market competition is consolidated in nature with leading players accounting for 80% of the total share

What Challenges limit the Growth Potential of the Market?

Stiff competition from alternate products is likely to limit the otherwise strong growth potential.

What is the Growth Outlook for the Recombinant Vaccines Market?

As per the demand analysis, the recombinant vaccines market is likely to record a CAGR of 8.75% through 2032.

How did the Market Perform in 2022?

The recombinant vaccines market size grew to US$ 42.08 billion in 2022.

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

    2.3. Exclusion and Inclusion

    2.4. Target Market Analysis (US$ Mn), 2018

        2.4.1. Global Filtration Market

        2.4.2. Global Membrane Market

3. Market Dynamics

    3.1. Macro-Economic Factors

    3.2. Market Dynamics

        3.2.1. Drivers

        3.2.2. Restraints

        3.2.3. Trends

4. Key Inclusions

    4.1. Pricing Analysis

    4.2. Pipeline Analysis

5. North America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    5.1. Introduction

    5.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017

        5.2.1. U.S.

        5.2.2. Canada

    5.3. Market Value (US$ Mn) Forecast By Country, 2018-2028

    5.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        5.4.1. Subunit Recombinant Vaccines

        5.4.2. Attenuated Recombinant Vaccines

        5.4.3. Vector Recombinant Vaccines

    5.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    5.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        5.6.1. Human

        5.6.2. Veterinary

    5.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    5.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        5.8.1. Hospitals

        5.8.2. Private Clinics & Dispensaries

        5.8.3. Retail Pharmacies

        5.8.4. Others

    5.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    5.10. Market Attractiveness Analysis

        5.10.1. By Country

        5.10.2. By Product Type

        5.10.3. By Application

        5.10.4. By Distribution Channel

    5.11. Drivers and Restraints: Impact Analysis

    5.12. Key Market Participants – Intensity Mapping

6. Latin America Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    6.1. Introduction

    6.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        6.2.1. Brazil

        6.2.2. Mexico

        6.2.3. Argentina

        6.2.4. Rest of Latin America

    6.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    6.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        6.4.1. Subunit Recombinant Vaccines

        6.4.2. Attenuated Recombinant Vaccines

        6.4.3. Vector Recombinant Vaccines

    6.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    6.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        6.6.1. Human

        6.6.2. Veterinary

    6.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    6.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        6.8.1. Hospitals

        6.8.2. Private Clinics & Dispensaries

        6.8.3. Retail Pharmacies

        6.8.4. Others

    6.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    6.10. Market Attractiveness Analysis

        6.10.1. By Country

        6.10.2. By Product Type

        6.10.3. By Application

        6.10.4. By Distribution Channel

    6.11. Drivers and Restraints: Impact Analysis

    6.12. Key Market Participants – Intensity Mapping

7. Western Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    7.1. Introduction

    7.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        7.2.1. Germany

        7.2.2. U.K

        7.2.3. France

        7.2.4. Italy

        7.2.5. Spain

        7.2.6. Nordics

        7.2.7. Benelux

        7.2.8. Rest of Western Europe

    7.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    7.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        7.4.1. Subunit Recombinant Vaccines

        7.4.2. Attenuated Recombinant Vaccines

        7.4.3. Vector Recombinant Vaccines

    7.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    7.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        7.6.1. Human

        7.6.2. Veterinary

    7.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    7.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        7.8.1. Hospitals

        7.8.2. Private Clinics & Dispensaries

        7.8.3. Retail Pharmacies

        7.8.4. Others

    7.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    7.10. Market Attractiveness Analysis

        7.10.1. By Country

        7.10.2. By Product Type

        7.10.3. By Application

        7.10.4. By Distribution Channel

    7.11. Drivers and Restraints: Impact Analysis

    7.12. Key Market Participants – Intensity Mapping

8. Eastern Europe Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    8.1. Introduction

    8.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        8.2.1. Russia

        8.2.2. Poland

        8.2.3. Rest of Eastern Europe

    8.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    8.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        8.4.1. Subunit Recombinant Vaccines

        8.4.2. Attenuated Recombinant Vaccines

        8.4.3. Vector Recombinant Vaccines

    8.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    8.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        8.6.1. Human

        8.6.2. Veterinary

    8.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    8.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        8.8.1. Hospitals

        8.8.2. Private Clinics & Dispensaries

        8.8.3. Retail Pharmacies

        8.8.4. Others

    8.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    8.10. Market Attractiveness Analysis

        8.10.1. By Country

        8.10.2. By Product Type

        8.10.3. By Application

        8.10.4. By Distribution Channel

    8.11. Drivers and Restraints: Impact Analysis

    8.12. Key Market Participants – Intensity Mapping

9. Asia Pacific Excluding China & Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    9.1. Introduction

    9.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        9.2.1. India

        9.2.2. China

        9.2.3. Australia and New Zealand

        9.2.4. ASEAN

        9.2.5. Rest of APECJ

    9.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    9.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        9.4.1. Subunit Recombinant Vaccines

        9.4.2. Attenuated Recombinant Vaccines

        9.4.3. Vector Recombinant Vaccines

    9.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    9.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        9.6.1. Human

        9.6.2. Veterinary

    9.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    9.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        9.8.1. Hospitals

        9.8.2. Private Clinics & Dispensaries

        9.8.3. Retail Pharmacies

        9.8.4. Others

    9.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    9.10. Market Attractiveness Analysis

        9.10.1. By Country

        9.10.2. By Product Type

        9.10.3. By Application

        9.10.4. By Distribution Channel

    9.11. Drivers and Restraints: Impact Analysis

    9.12. Key Market Participants – Intensity Mapping

10. Japan Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    10.1. Introduction

    10.2. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        10.2.1. Subunit Recombinant Vaccines

        10.2.2. Attenuated Recombinant Vaccines

        10.2.3. Vector Recombinant Vaccines

    10.3. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    10.4. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        10.4.1. Human

        10.4.2. Veterinary

    10.5. Market Value(US$ Mn) Forecast By Application, 2018-2028

    10.6. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        10.6.1. Hospitals

        10.6.2. Private Clinics & Dispensaries

        10.6.3. Retail Pharmacies

        10.6.4. Others

    10.7. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    10.8. Market Attractiveness Analysis

        10.8.1. By Product Type

        10.8.2. By Application

        10.8.3. By Distribution Channel

    10.9. Drivers and Restraints: Impact Analysis

    10.10. Key Market Participants – Intensity Mapping

11. Middle East and Africa Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    11.1. Introduction

    11.2. Historical Market Value(US$ Mn) Analysis By Country, 2013-2017

        11.2.1. GCC Countries

        11.2.2. South Africa

        11.2.3. Rest of Middle East and Africa

    11.3. Market Value(US$ Mn) Forecast By Country, 2018-2028

    11.4. Historical Market Value (US$ Mn) Analysis By Product Type, 2013-2017

        11.4.1. Subunit Recombinant Vaccines

        11.4.2. Attenuated Recombinant Vaccines

        11.4.3. Vector Recombinant Vaccines

    11.5. Market Value (US$ Mn) Forecast By Product Type, 2018-2028

    11.6. Historical Market Value(US$ Mn) Trend Analysis By Application, 2013-2017

        11.6.1. Human

        11.6.2. Veterinary

    11.7. Market Value(US$ Mn) Forecast By Application, 2018-2028

    11.8. Historical Market Value(US$ Mn) Trend Analysis By Distribution Channel, 2013-2017

        11.8.1. Human

        11.8.2. Veterinary

    11.9. Market Value(US$ Mn) Forecast By Distribution Channel, 2018-2028

    11.10. Market Attractiveness Analysis

        11.10.1. By Country

        11.10.2. By Product Type

        11.10.3. By Application

        11.10.4. By Distribution Channel

    11.11. Drivers and Restraints: Impact Analysis

    11.12. Key Market Participants – Intensity Mapping

12. Market Structure Analysis

    12.1. Market Structure by Tier

    12.2. Market Share Analysis (2017)

13. Competition Analysis

    13.1. Competition Dashboard

    13.2. Company Profiles

        13.2.1. GlaxoSmithKline Plc

            13.2.1.1. Overview of Division & Business Unit

            13.2.1.2. Analyst Commentary

            13.2.1.3. Key Developments

            13.2.1.4. Key Financials

        13.2.2. MERCK & CO., INC

        13.2.3. Dynavax Technologies Corporation

        13.2.4. Sanofi Pasteur

        13.2.5. Bharat Biotech

        13.2.6. Indian Immunologicals Limited

        13.2.7. Serum Institute of India Pvt. Ltd.

        13.2.8. LG Chem

        13.2.9. Sinovac Biotech Ltd

        13.2.10. Pfizer

        13.2.11. C.H. Boehringer Sohn AG & Co.KG

14. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028 By Region

    14.1. Introduction / Key Findings

    14.2. Historical Market Value(US$ Mn) Analysis By Region

        14.2.1. North America

        14.2.2. Latin America

        14.2.3. Western Europe

        14.2.4. Eastern Europe

        14.2.5. Asia Pacific Excluding Japan China

        14.2.6. Japan

        14.2.7. Middle East and Africa

    14.3. Market Value(US$ Mn) Forecast By Region

    14.4. Market Attractiveness Analysis By Region

15. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Product Type

    15.1. Introduction/Key Finding

    15.2. Historical Market Value(US$ Mn) Analysis By Product Type, 2013-2017

        15.2.1. Subunit Recombinant Vaccines

        15.2.2. Attenuated Recombinant Vaccines

        15.2.3. Vector Recombinant Vaccines

    15.3. Market Value(US$ Mn) Forecast By Product Type, 2018-2028

    15.4. Market Attractiveness Analysis By Product Type

16. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Application

    16.1. Introduction/Key Finding

    16.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017

        16.2.1. Human

        16.2.2. Veterinary

    16.3. Market Value(US$ Mn) Forecast By Application, 2018-2028

    16.4. Market Attractiveness Analysis By Application

17. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028, By Distribution Channel

    17.1. Introduction/Key Finding

    17.2. Historical Market Value(US$ Mn) Analysis By Application, 2013-2017

        17.2.1. Hospitals

        17.2.2. Private Clinics & Dispensaries

        17.2.3. Retail Pharmacies

        17.2.4. Others

    17.3. Market Value(US$ Mn) Forecast By Application, 2018-2028

    17.4. Market Attractiveness Analysis By Application

18. Global Recombinant Vaccines Analysis 2013–2017 and Forecast 2018–2028

    18.1. Market Value Share Analysis By All Segment

    18.2. Y-o-Y Growth Analysis By All Segment

    18.3. Absolute $ Opportunity

19. Assumptions and Acronyms Used

20. Research Methodology

Explore Healthcare Insights

View Reports

Recombinant Vaccines Market